Y Intercept Hong Kong Ltd Boosts Holdings in Sarepta Therapeutics, Inc. $SRPT

Y Intercept Hong Kong Ltd raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1,736.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 870,181 shares of the biotechnology company’s stock after purchasing an additional 822,799 shares during the quarter. Sarepta Therapeutics accounts for approximately 0.4% of Y Intercept Hong Kong Ltd’s investment portfolio, making the stock its 25th biggest holding. Y Intercept Hong Kong Ltd owned 0.89% of Sarepta Therapeutics worth $14,880,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 300 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at about $44,000. Pandora Wealth Inc. acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at about $45,000. Brooklyn Investment Group grew its position in shares of Sarepta Therapeutics by 450.4% during the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 590 shares during the period. Finally, Blue Trust Inc. grew its position in shares of Sarepta Therapeutics by 542.3% during the 2nd quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 2,771 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Trading Up 4.2%

Shares of Sarepta Therapeutics stock opened at $22.81 on Monday. The firm has a market capitalization of $2.23 billion, a PE ratio of -26.22 and a beta of 0.51. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81. The firm’s 50-day moving average price is $19.90 and its 200 day moving average price is $27.97. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. During the same period last year, the company posted $0.07 EPS. Sarepta Therapeutics’s quarterly revenue was up 68.4% compared to the same quarter last year. On average, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SRPT shares. Leerink Partners raised their target price on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a research report on Tuesday, September 9th. Deutsche Bank Aktiengesellschaft raised their target price on Sarepta Therapeutics to $12.00 and gave the company a “sell” rating in a research report on Friday, August 15th. Robert W. Baird raised their target price on Sarepta Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Jefferies Financial Group decreased their price target on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday, July 24th. Eight analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $34.46.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.